However, some patients have anecdotally reported feeling irritable, anxious, or experiencing mood fluctuations
A May 2024 survey from the International Foundation of Employee Benefit Plans found that 34% of employers covered GLP-1 drugs, up from 26% in 2023
Clinical trial data from the PIONEER programmewhich evaluated oral semaglutide across diverse patient populationsdid not demonstrate clinically significant elevations in liver transaminases (ALT and AST) compared to placebo or active comparators
Seim I, Jeffery PL, de Amorim L, Walpole CM, Fung J, Whiteside EJ, et al
The SURPASS-2 trial (A Study of Tirzepatide versus Semaglutide Once Weekly as an Add-On Therapy to Metformin in Participants with Type 2 Diabetes) compared the efficacy of different doses of tirzepatide with semaglutide 1 mg in patients with poorly controlled diabetes on metformin monotherapy
N., Wharton, S., Connery, L., Alves, B., & Stefanski, A